Dry extracts of ginkgo leaves are considered promising drugs for improving age-related cognitive impairment. A study compared the phytochemical composition of fourteen medicines containing ginkgo that have been approved by German health authorities for this indication and revealed some considerable differences in the proportion of proanthocyanidins (PACs).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
- PHYTOTHERAPIE PRAXIS
Related Topics
You May Also Like
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Interview
“On par with the gold standards for trauma”
- Psychology: Emotional Freedom Techniques (EFT)
Emotional Healing Through Tapping
- Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?
Treat-to-Target – Consensus Recommendations for GC Tapering and the Use of DMARDs
- Psychedelic-assisted therapy
Current status of PAT
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Psoriasis and Obesity: Effects of Incretin-Based Therapies
Clinical trials shed light on the potential of semaglutide, liraglutide, and tirzepatide
- Eosinophils in the Blood in COPD